Determining clinically important changes in range of motion in patients with Dupuytren's Contracture: secondary analysis of the randomized, double-blind, placebo-controlled CORD I study.

@article{Witthaut2011DeterminingCI,
  title={Determining clinically important changes in range of motion in patients with Dupuytren's Contracture: secondary analysis of the randomized, double-blind, placebo-controlled CORD I study.},
  author={J{\"o}rg Witthaut and Andrew G. Bushmakin and Robert A. Gerber and Joseph C. Cappelleri and Marie-Pierre Hellio Le Graverand-Gastineau},
  journal={Clinical drug investigation},
  year={2011},
  volume={31 11},
  pages={791-8}
}
BACKGROUND AND OBJECTIVE Injectable collagenase Clostridium histolyticum is efficacious in correcting Dupuytren's contracture as assessed by changes in the angle of contracture and range of motion (ROM). However, clinically important changes in ROM have not been evaluated in depth. The objective of this secondary analysis of the CORD I trial was to identify severity levels using baseline ROM, estimate a clinically important difference (CID) for ROM, and link the results to collagenase treatment… CONTINUE READING